Ipilimumab in melanoma with limited brain metastases treated with stereotactic radiosurgery

Melanoma Research

Volumn 23, Issue 3, 2013, Pages 191-195

  Mathew, Maya ^a   Tam, Moses ^a   Ott, Patrick A ^a   Pavlick, Anna C ^a   Rush, Stephen C ^a,b   Donahue, Bernadine R ^a,b   Golfinos, John G ^b   Parker, Erik C ^b   Huang, Paul P ^b   Narayana, Ashwatha ^a,b  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b Department of Neurosurgery ^*  (United States)

Author keywords

brain metastases; ipilimumab; melanoma; stereotactic radiosurgery

Indexed keywords

IPILIMUMAB;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER MORTALITY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; DRUG EFFICACY; FEMALE; GAMMA KNIFE RADIOSURGERY; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTATIC MELANOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RADIATION DOSE; RETROSPECTIVE STUDY; STEREOTACTIC RADIOSURGERY; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; RADIOSURGERY; RETROSPECTIVE STUDIES; SKIN NEOPLASMS;

EID: 84877043331     PISSN: 09608931     EISSN: 14735636     Source Type: Journal    
DOI: 10.1097/CMR.0b013e32835f3d90     Document Type: Article

References (18)

1. Staudt M, Lasithiotakis K, Leiter U, Meier F, Eigentler T, Bamberg M, et al. Determinants of survival in patients with brain metastases from cutaneous melanoma. Br J Cancer 2010; 102:1213-1218.
2. Bafaloukos D, Gogas H. The treatment of brain metastases in melanoma patients. Cancer Treat Rev 2004; 30:515-520.
3. Hwu W-J, Lis E, Menell JH, Panageas KS, Lamb LA, Merrell J, et al. Temozolomide plus thalidomide in patients with brain metastases from melanoma. Cancer 2005; 103:2590-2597.
4. Fife KM, Colman MH, Stevens GN, Firth IC, Moon D, Shannon KF, et al. Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol 2004; 22:1293-1300.
5. Gaudy-Marqueste C, Regis JM, Muracciole X, Laurans R, Richard MA, Bonerandi JJ, et al. Gamma-Knife radiosurgery in the management of melanoma patients with brain metastases: a series of 106 patients without whole-brain radiotherapy. Int J Radiat Oncol Biol Phys 2006; 65:809-816.
6. Selek U, Chang EL, Hassenbusch SJ 3rd, Shiu AS, Lang FF, Allen P, et al. Stereotactic radiosurgical treatment in 103 patients for 153 cerebral melanoma metastases. Int J Radiat Oncol Biol Phys 2004; 59:1097-1106.
7. Ascierto P, Marincola F, Ribas A. Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application. J Transl Med 2011; 9:196.
8. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363:711-723.
9. Robert C, Thomas L, Bondarenko I, O'Day S, MD JW, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011; 364:2517-2526.
10. Demaria S, Kawashima N, Yang AM, Devitt ML, Babb JS, Allison JP, et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res 2005; 11 (2 Pt 1):728-734.
11. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012; 366:925-931.
12. Macdonald DR, Cascino TL, Schold SC, Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 1990; 8:1277-1280.
13. Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990; 322:494-500.
14. Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, et al. Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 2007; 13:6681-6688.
15. Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 2012; 13: 459-465.
16. Knisely JP, Yu JB, Flanigan J, Sznol M, Kluger HM, Chiang VL. Radiosurgery for melanoma brain metastases in the ipilimumab era and the possibility of longer survival. J Neurosurg 2012; 117:227-233.
17. Fidler IJ. The role of the organ microenvironment in brain metastasis. Semin Cancer Biol 2011; 21:107-112.
18. Cecchelli R, Berezowski V, Lundquist S, Culot M, Renftel M, Dehouck MP, et al. Modelling of the blood-brain barrier in drug discovery and development. Nat Rev Drug Discov 2007; 6:650-661.